In Depth 22 Oct 2025 PCSK9’s second act: From antibodies to gene editing With Eli Lilly’s recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents. October 22, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Apr 2025 Seven biotechs to watch in the hepatitis B space Here we take a look at seven biotechs with clinical drug candidates on a quest to win regulatory approval to treat HBV. April 22, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2024 Resolution Therapeutics raises $85 million to advance its macrophage therapy Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round. October 3, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 12 Jul 2024How biotechs are revolutionizing acute on-chronic liver failure? Listen to our conversation with Genfit, a late-stage biopharma tackling acute on-chronic liver failure. July 12, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 19 Jun 2024 MASH candidates make a splash after first drug approval The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients. June 19, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 3 Apr 2024 Hepatitis B: are we edging closer to a cure? Find out whether we are closing in on a cure for hepatitis B – a virus affecting the liver that can cause acute and chronic disease. April 3, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 1 Mar 2024The final chapter in genomic medicines? Explore the future of genomic medicine with Tome Biosciences’ programmable genomic integration technique, set to revolutionize gene editing. March 1, 2024 Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Dec 2023 Five companies racing to bring their NASH treatments toward the finish line NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), where fat builds up on the liver, potentially leading to liver damage or cirrhosis. With no U.S. Food and Drug Administration (FDA)-approved treatments for the disease, many NASH companies are currently attempting to bring their candidates toward approval. In this article, we take a […] December 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 1 Dec 2023Ipsen drug gives hope for liver disease patients On the podcast this week, we are looking at recent advances in treating certain liver diseases. Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen, and she discusses a breakthrough treatment for primary biliary cholangitis and cholestatic liver disease. What is primary biliary cholangitis? Primary biliary […] December 1, 2023 Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Sep 2023 Five latest advancements in NASH research Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) – a condition where fat builds up in the liver, potentially causing liver damage or cirrhosis. Despite the severity of the disease, and the fact that approximately 25% of U.S. adults have NAFLD, while 5% have NASH, there is yet to be […] September 15, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 First drug discovered through 3D bioprinted tissue disease model Viscient Bio, Inc. has announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells. The company said it expects to develop the drug to treat non-alcoholic steatohepatitis (NASH), a growing epidemic disease that is believed to affect more than 10% of the U.S. […] May 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 Orphalan announces U.S. launch of drug to treat Wilson disease Orphalan SA, an international orphan drug development and commercialization company, has announced the commercial launch in the U.S. for Cuvrior. Cuvrior is a new trientine tetrahydrochloride (TETA-4HCl). It is now available for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to D-penicillamine. Cuvrior was approved by the United States […] April 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email